Hypogammaglobulinemia, a new risk factor for hepatitis B virus reactivation : about two cases.
| Journal | Volume 86 - 2023 |
| Issue | Fasc.3 - Case reports |
| Author(s) | F. de Leuze 1, V. Havelange 2, M-A. van Dievoet 3, Y. Horsmans 1, G. Dahlqvist 1 |
| Full article |
 PAGES 493-494 VIEW FREE PDF |
| DOI | 10.51821/86.3.10755 |
|
Affiliations: (1) Hepatogastroenterology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium
(2) Hematology unit, Cliniques Universitaires Saint-Luc, Brussels, Belgium (3) Laboratory department, Cliniques universitaires Saint-Luc, Brussels, Belgium |
|
Reactivation of the hepatitis B virus (HBV) with immunosuppressive status has been well established, mainly due to medications such as immunosuppressive therapy like cytotoxic chemotherapy, rituximab and biologic therapy, immunosuppression after solid and bone-marrow transplantation or long-term corticosteroids therapy. We report here two cases of HBV reactivation due to global hypogammaglobulinemia. Regular HBV serologic screening and PCR for HBV-DNA should be applied for each patient with primary immunosuppressive status and history of chronic HBV infection. The necessity of a preemptive treatment remains debated. Keywords: Hepatitis B reactivation, immunosuppression, hypogammaglobulinemia, common variable immunodeficiency. |
| The authors declare that they have no conflict of interest. |
|
© Acta Gastro-Enterologica Belgica. PMID 37814567 |
